Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD - A 1-year follow-up randomized, controlled trial

Respiratory Medicine

Volumn 96, Issue 6, 2002, Pages 424-431

  Gallefoss, Frode ^a   Bakke, Per Sigvald ^b  

^a Vest Agder Central Hospital   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

COPD; Cost analysis; Economics; Patient education; Randomized controlled trial

Indexed keywords

ANTIASTHMATIC AGENT;

ABSENTEEISM; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH ECONOMICS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSE; OUTPATIENT; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSIOTHERAPIST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRAVEL; TREATMENT PLANNING; ECONOMICS; MIDDLE AGED; SELF CARE;

COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION; PATIENT SATISFACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SELF CARE;

EID: 0036591412     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1293     Document Type: Article

References (25)

1. Buist A S. Worldwide trends in asthma morbidity and mortality. Bull Int Union Tuberc Lung Dis 1991; 66: 77-78.
2. Bakke P S, Baste V, Hanoa R, Gulsvik A. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991; 46: 863-870.
3. Anonymous. Oydvin, K, ed. Medication Consumption in Norway 1990-1994. Oslo, Norway: Norsk Medisinaldepot, 1994: 1.
4. Gallefoss, F. The effects of patient education in asthma and COPD - a randomized, controlled trial. Thesis, University of Bergen, Bergen, Norway, 2001; 1-213.
5. Weiss K B, Gergen P J, Hodgson T A. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862-866.
6. Gallefoss F, Bakke P S. Cost-effectiveness of self-management in asthmatics - a one year randomized controlled trial. Eur Respir J 2001; 17: 206-213.
7. Gallefoss F, Bakke P S. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. Respir Med 2000; 94: 279-287.
8. Gallefoss F, Bakke P S. Patient satisfaction with health care in asthmatics and patients with COPD before and after patient education. Eurn Respir J 2000; 94: 1057-1064.
9. Gallefoss F, Bakke P S, Kjærsgaard P. Quality of life assessment after patient education in a randomized controlled study on asthma and COPD. Am J Respir Crit Care Med 1999; 159: 812-817.
10. Gallefoss F, Bakke P S. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? Am J Respir Crit Care Med 1999; 160: 2000-2005.
11. Quanjer P H, Tammeling G J, Cotes J E, Pedersen O F, Peslin R, Yernault J C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 16 (Suppl.): 5-40.
12. Anonymous. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (Pt 2): S77-121.
13. Anthonisen N R, Wright E C. Bronchoidilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814-819.
14. Anonymous. Anatomical Therapeutic Chemical (ATC) Classification Index Including Defined Daily Doses (DDDs) for Plain Substances. WHO Collaborating Centre for Drug Statistics Methodology, 1994.
15. Anonymous. Applied Research and Communications Limited, ed. The Life Quality of Asthma. London, U.K: Allen & Hanburys, 1991: HS 9532-CP.
16. The Royal Social - and Health Department, ed. Pricelist DRG, 1994.
17. Standard fee schedule for the Norwegian Medical Association including National Health Insurance Reimbursement rates and block grants. The Norwegian Medical Association, 1994: 3.
18. Taraldset, A. Den norske Lægeforening, ed. The Norwegian Medical Association's Survey on Reinbursements from National Health Insurance Schemes, 1992.
19. Central Bureau of Statistics, N. ed. Mean Hourly Wage Rates for Industrial Workers. 1994, Table II.
20. Koopmanschap M A, Rutten F F, van Ineveld B M, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-189.
21. Drummond M F, O'Brien B, Stoddart G L, et al. In Drummond M F, O'Brien B, Stoddart G L et al., eds. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford: Oxford University Press, 1997.
22. Lang T A, Secic M, Ruff M K, ed. How to Report Statistics in Medicine. Annotated Guidelines for Authors, Editors and Reviewers, 1st ed. Philadelphia: American College of Physicians, 1997.
23. Altman D G. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-1312.
24. Torrance G W, Siegel J E, Luce B R. Cost-Effectiveness in Health and Medicine, 1st ed. Vol. 3, Framing and Designing the Cost-Effectiveness Analysis. New York: Oxford University Press, 1996: 54-81.
25. Jansson S A, Ericsson Å, Borg S, et al. The economic consequences for society of chronic obstructive pulmonary disease. Eur Respir J 2000; 16 (Suppl. 31, abstr. 268): 13s.